The shares of pharmaceutical company, specializing in developing, manufacturing, and marketing complex products for niche therapeutic areas have declined upto 19 percent following the Q3 results with an 80 percent decline in their Profit QoQ.
Price action
With a market capitalization of Rs. 17,764.12 crores on Thursday, the shares of Natco Pharma Limited down upto 19 percent making a low of Rs. 986.00 per share compared to its previous closing price of Rs. 1216.65 per share.
What Happened
Natco Pharma Limited engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas has announced its Q3 results.
Its Revenue from operations declined by 37 percent YoY from Rs. 759 Crores in Q3FY24 to Rs. 475 Crores in Q3FY25 and it was down by 65 percent QoQ from Rs. 1,371 Crores in Q2FY25 to Rs. 475 Crores in Q3FY25.
Its Net Profit declined by 38 percent YoY from Rs. 213 Crores in Q3FY24 to Rs. 132 Crores in Q3FY25 and it declined by 80 percent QoQ from Rs. 676 Crores in Q2FY25 to Rs. 132 Crores in Q3FY25.
The earnings per share (EPS) for the quarter stood at Rs. 7.43, compared to Rs. 37.81 in the previous quarter and Rs. 11.88 in the same quarter last year.
Furthermore, they have declared a third interim dividend of Rs. 1.50 per share (75 percent) per equity share of Rs.2 for the financial year 2024-25. The record date to determine eligible shareholders is set for 18th February 2025 and dividend payments will start from 28th February 2025.
Segment Revenue
The company’s revenue is primarily driven by two segments: the Pharmaceutical segment, which contributed Rs. 459.7 crore compared to Rs. 1,356.2 crores in the previous quarter, and the Agro Chemicals segment, which contributed Rs. 15.1 crore compared to Rs. 14.9 crore in the previous quarter.
About the Company
Natco Pharma Limited is an Indian multinational pharmaceutical company, specializing in the development, manufacturing, and marketing of generic and branded formulations. They focus on producing high-quality, affordable medicines across various therapeutic segments, including oncology, cardiology, and gastroenterology, and also engage in the production of active pharmaceutical ingredients (APIs).
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
